Moody Aldrich Partners’s Myriad Genetics MYGN Stock Holding History

Moody Aldrich Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-85,479	Closed	-$2.48M	–	110
2018 Q4	$2.48M	Buy	+85,479	New	+$3.08M	0.82%	51
2016 Q2	–	Sell	-6,640	Closed	-$249K	–	94
2016 Q1	$249K	Buy	+6,640	New	+$250K	0.52%	82

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Moody Aldrich Partners's MYGN Position: Q1 2019 in Review

Moody Aldrich Partners sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 85,479 shares — an estimated $2.48M sold.

Moody Aldrich Partners first reported a position in MYGN in Q1 2016 and held it in 2 quarters. The position peaked at $2.48M in Q4 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

Moody Aldrich Partners reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
Moody Aldrich Partners sold 85,479 Myriad Genetics shares in Q1 2019, an estimated $2.48M.
Moody Aldrich Partners first reported a position in Myriad Genetics in Q1 2016 and held it in 2 quarters.
Moody Aldrich Partners's Myriad Genetics position peaked at $2.48M in Q4 2018.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Moody Aldrich Partners's 13F filing for Q1 2019, filed 3 May 2019.